---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-22-004361"
form_type: "8-K"
ticker: "PMCB"
cik: "0001157075"
company_name: "PharmaCyte Biotech, Inc."
filed_at: "2022-06-15T23:59:59+00:00"
generated_at: "2026-06-25T01:31:14.429394+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# PharmaCyte defends board and strategy against Iroquois Capital; accelerates pancreatic cancer trial

## Summary
- Company expects to begin Phase 2b pancreatic cancer trial immediately upon FDA lifting clinical hold, saving ~6 months.
- Board plans to add capital markets experience; Iroquois has not recommended any candidate despite offer.
- New executive compensation agreements tie cash and equity bonuses to achievement of corporate goals.
- Company raised ~$90M in two capital raises and uplisted to Nasdaq; cash provides strategic advantage.
- Company reiterates strategy will deliver higher shareholder value over time; rejects Iroquois' characterizations.

## SEC filing metadata
- accession: 0001683168-22-004361
- form_type: 8-K
- ticker: PMCB
- cik: 0001157075
- company_name: PharmaCyte Biotech, Inc.
- filed_at: 2022-06-15T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1157075/000168316822004361/0001683168-22-004361-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1157075/000168316822004361/pharmacyte_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-22-004361
- JSON: https://secwatch.observer/filing/0001683168-22-004361.json
- Plain text: https://secwatch.observer/filing/0001683168-22-004361.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.